219 related articles for article (PubMed ID: 37590417)
1. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus.
Cross RW; Heinrich ML; Fenton KA; Borisevich V; Agans KN; Prasad AN; Woolsey C; Deer DJ; Dobias NS; Rowland MM; Lathigra R; Borrega R; Geisbert JB; Garry RF; Branco LM; Geisbert TW
Proc Natl Acad Sci U S A; 2023 Aug; 120(34):e2304876120. PubMed ID: 37590417
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates.
Woolsey C; Cross RW; Prasad AN; Agans KN; Borisevich V; Deer DJ; Dobias NS; Fears AC; Harrison MB; Heinrich ML; Fenton KA; Garry RF; Branco LM; Geisbert TW
Emerg Microbes Infect; 2024 Dec; 13(1):2301061. PubMed ID: 38164768
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus.
Cross RW; Fenton KA; Woolsey C; Prasad AN; Borisevich V; Agans KN; Deer DJ; Dobias NS; Fears AC; Heinrich ML; Geisbert JB; Garry RF; Branco LM; Geisbert TW
Cell Rep Med; 2024 Feb; 5(2):101392. PubMed ID: 38280377
[TBL] [Abstract][Full Text] [Related]
4. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever.
Cross RW; Woolsey C; Prasad AN; Borisevich V; Agans KN; Deer DJ; Geisbert JB; Dobias NS; Fenton KA; Geisbert TW
Cell Rep; 2022 Jul; 40(3):111094. PubMed ID: 35858566
[TBL] [Abstract][Full Text] [Related]
5. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.
Mire CE; Cross RW; Geisbert JB; Borisevich V; Agans KN; Deer DJ; Heinrich ML; Rowland MM; Goba A; Momoh M; Boisen ML; Grant DS; Fullah M; Khan SH; Fenton KA; Robinson JE; Branco LM; Garry RF; Geisbert TW
Nat Med; 2017 Oct; 23(10):1146-1149. PubMed ID: 28869611
[TBL] [Abstract][Full Text] [Related]
6. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.
Jiang J; Banglore P; Cashman KA; Schmaljohn CS; Schultheis K; Pugh H; Nguyen J; Humeau LM; Broderick KE; Ramos SJ
Hum Vaccin Immunother; 2019; 15(9):2066-2074. PubMed ID: 31071008
[TBL] [Abstract][Full Text] [Related]
8. Antibody therapy for Lassa fever.
Cross RW; Hastie KM; Mire CE; Robinson JE; Geisbert TW; Branco LM; Ollmann Saphire E; Garry RF
Curr Opin Virol; 2019 Aug; 37():97-104. PubMed ID: 31401518
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing Antibodies against Lassa Virus Lineage I.
Buck TK; Enriquez AS; Schendel SL; Zandonatti MA; Harkins SS; Li H; Moon-Walker A; Robinson JE; Branco LM; Garry RF; Saphire EO; Hastie KM
mBio; 2022 Aug; 13(4):e0127822. PubMed ID: 35730904
[TBL] [Abstract][Full Text] [Related]
10. The search for animal models for Lassa fever vaccine development.
Lukashevich IS
Expert Rev Vaccines; 2013 Jan; 12(1):71-86. PubMed ID: 23256740
[TBL] [Abstract][Full Text] [Related]
11. Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies.
Perrett HR; Brouwer PJM; Hurtado J; Newby ML; Liu L; Müller-Kräuter H; Müller Aguirre S; Burger JA; Bouhuijs JH; Gibson G; Messmer T; Schieffelin JS; Antanasijevic A; Boons GJ; Strecker T; Crispin M; Sanders RW; Briney B; Ward AB
Cell Rep; 2023 May; 42(5):112524. PubMed ID: 37209096
[TBL] [Abstract][Full Text] [Related]
12. Current research for a vaccine against Lassa hemorrhagic fever virus.
Warner BM; Safronetz D; Stein DR
Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299
[TBL] [Abstract][Full Text] [Related]
13. Differential pathogenesis of closely related 2018 Nigerian outbreak clade III Lassa virus isolates.
Stein DR; Warner BM; Audet J; Soule G; Siragam V; Sroga P; Griffin BD; Leung A; Grolla A; Tierney K; Albietz A; Kobasa D; Musa AS; Ahmad A; Akinpelu AM; Mba N; Rosenke R; Scott DP; Saturday G; Ihekweazu C; Safronetz D
PLoS Pathog; 2021 Oct; 17(10):e1009966. PubMed ID: 34634087
[TBL] [Abstract][Full Text] [Related]
14. Identification of Common CD8
Sakabe S; Hartnett JN; Ngo N; Goba A; Momoh M; Sandi JD; Kanneh L; Cubitt B; Garcia SD; Ware BC; Kotliar D; Robles-Sikisaka R; Gangavarapu K; Branco LM; Eromon P; Odia I; Ogbaini-Emovon E; Folarin O; Okogbenin S; Okokhere PO; Happi C; Sabeti PC; Andersen KG; Garry RF; de la Torre JC; Grant DS; Schieffelin JS; Oldstone MBA; Sullivan BM
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269122
[TBL] [Abstract][Full Text] [Related]
15. Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages.
Heinrich ML; Boisen ML; Nelson DKS; Bush DJ; Cross RW; Koval AP; Hoffmann AR; Beddingfield BJ; Hastie KM; Rowland MM; Aimukanova I; Koval S; Lathigra R; Borisevich V; Momoh M; Sandi JD; Goba A; Odia L; Baimba F; Aiyepada JO; Ebo B; Eromon P; Ugwu C; Folarin O; Olumade T; Onyechi MN; Etafo J; Adeyemi R; Ella EE; Aminu M; Gomerep SS; Eke MA; Ogunsanya O; Akpede GO; Asogun DO; Okogbenin SA; Okokhere PO; Holst J; Shaffer JG; Schieffelin JS; Geisbert TW; Saphire EO; Happi CT; Grant DS; Garry RF; Branco LM
Sci Rep; 2020 Sep; 10(1):16030. PubMed ID: 32994446
[TBL] [Abstract][Full Text] [Related]
16. Lassa fever - the road ahead.
Garry RF
Nat Rev Microbiol; 2023 Feb; 21(2):87-96. PubMed ID: 36097163
[TBL] [Abstract][Full Text] [Related]
17. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
Carnec X; Mateo M; Page A; Reynard S; Hortion J; Picard C; Yekwa E; Barrot L; Barron S; Vallve A; Raoul H; Carbonnelle C; Ferron F; Baize S
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593043
[TBL] [Abstract][Full Text] [Related]
18. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.
Robinson JE; Hastie KM; Cross RW; Yenni RE; Elliott DH; Rouelle JA; Kannadka CB; Smira AA; Garry CE; Bradley BT; Yu H; Shaffer JG; Boisen ML; Hartnett JN; Zandonatti MA; Rowland MM; Heinrich ML; Martínez-Sobrido L; Cheng B; de la Torre JC; Andersen KG; Goba A; Momoh M; Fullah M; Gbakie M; Kanneh L; Koroma VJ; Fonnie R; Jalloh SC; Kargbo B; Vandi MA; Gbetuwa M; Ikponmwosa O; Asogun DA; Okokhere PO; Follarin OA; Schieffelin JS; Pitts KR; Geisbert JB; Kulakoski PC; Wilson RB; Happi CT; Sabeti PC; Gevao SM; Khan SH; Grant DS; Geisbert TW; Saphire EO; Branco LM; Garry RF
Nat Commun; 2016 May; 7():11544. PubMed ID: 27161536
[TBL] [Abstract][Full Text] [Related]
19. Vaccine platforms to control Lassa fever.
Lukashevich IS; Pushko P
Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
[TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria.
Ugwu C; Olumade T; Nwakpakpa E; Onyia V; Odeh E; Duruiheoma RO; Ojide CK; Eke MA; Nwafor IE; Chika-Igwenyi N; Abu AM; Azuogu B; Ajayi N; Ogah E; Ayodeji O; Abejegah C; Adedosu N; Oyejide N; Abah S; Omidele A; Ingbian W; Osoba E; Eromon P; Oluniyi P; Ogunsanya O; Happi A; Otuh P; Nadesalingam A; Carnell G; Krause N; Aguinam E; Kinsley R; Storisteanu DML; Tonks P; Nelson D; McAlister C; Boisen M; Garry R; Wright E; Temperton N; Frost S; Heeney JL; Happi C
Sci Rep; 2022 Dec; 12(1):22330. PubMed ID: 36567369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
